Last reviewed · How we verify

Lopinavir and Ritonavir Tablets — Competitive Intelligence Brief

Lopinavir and Ritonavir Tablets (Lopinavir and Ritonavir Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lopinavir and Ritonavir Tablets (Lopinavir and Ritonavir Tablets) — DualityBio Inc.. Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lopinavir and Ritonavir Tablets TARGET Lopinavir and Ritonavir Tablets DualityBio Inc. marketed HIV protease inhibitor HIV protease
Darunavir/Ritonavir (Prezista) Darunavir/Ritonavir (Prezista) Kowa Research Institute, Inc. marketed HIV protease inhibitor HIV protease
Maraviroc, Darunavir/r Maraviroc, Darunavir/r Catholic University of the Sacred Heart marketed Antiretroviral combination (CCR5 antagonist + protease inhibitor) CCR5 co-receptor (maraviroc); HIV protease (darunavir)
AZT+3TC+IDV+RTV AZT+3TC+IDV+RTV Hospital Clinic of Barcelona marketed Antiretroviral combination therapy (NRTI + PI) HIV reverse transcriptase; HIV protease
Reyataz + Epzicom Reyataz + Epzicom ViiV Healthcare marketed Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease; HIV reverse transcriptase
Lopinavir / Ritonavir Lopinavir / Ritonavir Baqiyatallah Medical Sciences University marketed HIV protease inhibitor HIV protease
PEP PEP Christopher J. McLeod marketed Protease inhibitor HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

  1. Bristol-Myers Squibb · 5 drugs in this class
  2. ViiV Healthcare · 3 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Drugs for Neglected Diseases · 2 drugs in this class
  5. Germans Trias i Pujol Hospital · 2 drugs in this class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
  9. Far East Bio-Tec Co., Ltd · 1 drug in this class
  10. Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lopinavir and Ritonavir Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/lopinavir-and-ritonavir-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: